Alphabet’s life sciences offshoot Verily said Friday that it has raised $1 billion to fuel its next stage of development — one that will be steered by a new corporate leader as CEO Andy Conrad plans to shift to an advisory role.
Subscribe to our newsletter
Stay on top of the latest news, trends and insights on healthcare digital transformation.
